Amytrx Therapeutics
AL - BirminghamBiotechnology
Focus: Amytrx Therapeutics is a peptide-focused biotech company specializing in immunology-based therapeutics, founded in 1985 and headquartered in Birmingham, Alabama. As a publicly traded company with early-stage pipeline assets, it operates at a modest scale relative to larger biotechs.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Amytrx Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Amytrx Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
AMTX-100
Atopic DermatitisClinical Trials (1)
NCT04313400Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis
Phase 1/2Help build intelligence for Amytrx Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.